CL2024000020A1 - Compuestos para la degradación selectiva de las proteínas irak4 - Google Patents
Compuestos para la degradación selectiva de las proteínas irak4Info
- Publication number
- CL2024000020A1 CL2024000020A1 CL2024000020A CL2024000020A CL2024000020A1 CL 2024000020 A1 CL2024000020 A1 CL 2024000020A1 CL 2024000020 A CL2024000020 A CL 2024000020A CL 2024000020 A CL2024000020 A CL 2024000020A CL 2024000020 A1 CL2024000020 A1 CL 2024000020A1
- Authority
- CL
- Chile
- Prior art keywords
- irak4
- proteins
- compounds
- irak
- dsm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219160P | 2021-07-07 | 2021-07-07 | |
| US202263354017P | 2022-06-21 | 2022-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000020A1 true CL2024000020A1 (es) | 2024-05-31 |
Family
ID=82748311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000020A CL2024000020A1 (es) | 2021-07-07 | 2024-01-04 | Compuestos para la degradación selectiva de las proteínas irak4 |
Country Status (14)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| WO2023152349A1 (en) * | 2022-02-14 | 2023-08-17 | Astrazeneca Ab | Irak4 inhibitors |
| EP4428134A1 (en) * | 2023-03-10 | 2024-09-11 | Dark Blue Therapeutics Ltd | Protac degraders of mllt1 and/or mllt3 |
| EP4389747A1 (en) * | 2022-12-21 | 2024-06-26 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4638447A1 (en) * | 2022-12-21 | 2025-10-29 | Dark Blue Therapeutics Ltd | Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors |
| EP4656640A4 (en) * | 2023-03-03 | 2026-08-19 | Shanghai Qilu Pharmaceutical Res And Development Centre Ltd | Iraq's Degradation Agent 4 and its Use |
| US20240374588A1 (en) * | 2023-04-07 | 2024-11-14 | Astrazeneca Ab | Irak4 protacs |
| KR20260005340A (ko) * | 2023-05-30 | 2026-01-09 | 상하이 후이룬 파마슈티컬 컴퍼니 리미티드 | 트리시클릭 화합물, 이의 제조 방법 및 적용 |
| EP4759807A1 (en) | 2023-08-11 | 2026-06-17 | Shenzhen Zhongge Biological Technology Co., Ltd. | Proteolysis targeting chimera compound for degrading irak4 and use thereof |
| EP4763839A1 (en) * | 2023-08-15 | 2026-06-24 | Pamplona Therapeutics (Shenzhen) Co., Ltd. | Compound targeting irak protein inhibition or degradation and use thereof |
| WO2025106480A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025106472A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| US20250197411A1 (en) * | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| CN119019427B (zh) * | 2024-08-14 | 2026-01-20 | 泰诺瑞(天津)生物科技有限责任公司 | 一种三并环类化合物及其应用 |
| US20260146050A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes |
| WO2026139448A1 (en) | 2024-12-23 | 2026-07-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| WO2026156134A1 (en) | 2025-01-17 | 2026-07-23 | F. Hoffmann-La Roche Ag | Tyk2 degraders |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| GB9208740D0 (en) | 1992-04-23 | 1992-06-10 | Glaxo Group Ltd | Chemical compounds |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| CA2988414C (en) | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017250076B2 (en) | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP3634960A1 (en) | 2017-06-09 | 2020-04-15 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2019023553A1 (en) | 2017-07-28 | 2019-01-31 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CA3095912A1 (en) | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| KR20220027196A (ko) * | 2019-06-27 | 2022-03-07 | 바이오젠 엠에이 인코포레이티드 | 이미다조[1,2-a]피리디닐 유도체 및 질병의 치료에서 이것들의 용도 |
| CN114585609B (zh) * | 2019-06-27 | 2024-07-30 | 比奥根Ma公司 | 2h-吲唑衍生物及其在疾病治疗中的用途 |
| PH12022500002A1 (en) * | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) * | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| CN116194453A (zh) | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
| US20230122219A1 (en) * | 2020-02-03 | 2023-04-20 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4267576A1 (en) * | 2020-12-22 | 2023-11-01 | Biogen MA Inc. | Imidazo[1,2-a]pyridine derivatives as irak4 inhibitors and their use in the treatment of disease |
| MX2023012981A (es) * | 2021-05-03 | 2024-01-11 | Nurix Therapeutics Inc | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. |
-
2022
- 2022-07-07 CA CA3224732A patent/CA3224732A1/en active Pending
- 2022-07-07 WO PCT/US2022/073522 patent/WO2023283610A1/en not_active Ceased
- 2022-07-07 AU AU2022308734A patent/AU2022308734A1/en active Pending
- 2022-07-07 EP EP22748718.8A patent/EP4367113A1/en active Pending
- 2022-07-07 KR KR1020247004514A patent/KR20240035526A/ko active Pending
- 2022-07-07 UY UY0001039844A patent/UY39844A/es unknown
- 2022-07-07 MX MX2024000395A patent/MX2024000395A/es unknown
- 2022-07-07 JP JP2024500319A patent/JP2024527570A/ja active Pending
- 2022-07-07 TW TW111125548A patent/TW202321236A/zh unknown
- 2022-07-07 IL IL309941A patent/IL309941A/en unknown
- 2022-07-07 US US18/576,940 patent/US20240343733A1/en active Pending
-
2024
- 2024-01-04 JO JOJO/P/2024/0002A patent/JOP20240002A1/ar unknown
- 2024-01-04 CL CL2024000020A patent/CL2024000020A1/es unknown
- 2024-02-05 CO CONC2024/0001193A patent/CO2024001193A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024001193A2 (es) | 2024-05-20 |
| IL309941A (en) | 2024-03-01 |
| JOP20240002A1 (ar) | 2024-01-04 |
| WO2023283610A1 (en) | 2023-01-12 |
| MX2024000395A (es) | 2024-04-05 |
| TW202321236A (zh) | 2023-06-01 |
| US20240343733A1 (en) | 2024-10-17 |
| EP4367113A1 (en) | 2024-05-15 |
| KR20240035526A (ko) | 2024-03-15 |
| AU2022308734A1 (en) | 2024-02-22 |
| JP2024527570A (ja) | 2024-07-25 |
| UY39844A (es) | 2023-01-31 |
| CA3224732A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001193A2 (es) | Compuestos para la degradación selectiva de las proteínas irak4 | |
| AR125768A1 (es) | Compuestos para la degradación dirigida de la tirosina cinasa de bruton | |
| AR121047A1 (es) | Inhibidores de map4k1 | |
| CO2024012743A2 (es) | Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias | |
| UY27169A1 (es) | Derivados del ácido isoftálico como inhibidores de metalproteinasas de la matriz | |
| AR132340A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| BR112022000064A2 (pt) | Inibidores de hpk1 e usos dos mesmos | |
| BR112018067775A2 (pt) | inibidores de mcl-1 indol substituído | |
| AR046614A1 (es) | Derivados espirociclicos del acido tetramico 2-halogeno-6-alquil-fenil substituidos. | |
| GT200300296A (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| CR9221A (es) | Procesos para preparar eteres aromaticos | |
| UY36712A (es) | Derivados de pirimidiniloxi benceno como herbicidas | |
| CL2020003065A1 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| UY28964A1 (es) | Agentes desinfectantes para la lucha contra hongos fitopatogenos | |
| DE602006010433D1 (de) | Für die behandlung von obesitas geeignete tricyclische amidderivate | |
| UY31162A1 (es) | Espiroindolinas como moduladores de receptores de quimioquinas | |
| AR126397A1 (es) | Compuestos para la degradación selectiva de las proteínas irak4 | |
| CO2021017740A2 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
| UY28006A1 (es) | Agonistas ppar quirales | |
| UY39995A (es) | Compuestos de pirrolopiridazina como antihelmínticos | |
| MX9606494A (es) | Compuestos organicos. | |
| GT200600326A (es) | Diazepinoquinolinas, sintesis de las mismas e intermediarios de las mismas |